200 related articles for article (PubMed ID: 38761900)
1. Network-based approach for drug repurposing against mpox.
Tang K; Sun Q; Zeng J; Tang J; Cheng P; Qiu Z; Long H; Chen Y; Zhang C; Wei J; Qiu X; Jiang G; Fang Q; Sun L; Sun C; Du X
Int J Biol Macromol; 2024 Jun; 270(Pt 2):132468. PubMed ID: 38761900
[TBL] [Abstract][Full Text] [Related]
2. The discovery of novel antivirals for the treatment of mpox: is drug repurposing the answer?
Ezat AA; Abduljalil JM; Elghareib AM; Samir A; Elfiky AA
Expert Opin Drug Discov; 2023 May; 18(5):551-561. PubMed ID: 37032577
[TBL] [Abstract][Full Text] [Related]
3. Expression analysis and mapping of Viral-Host Protein interactions of Poxviridae suggests a lead candidate molecule targeting Mpox.
Loganathan T; Fletcher J; Abraham P; Kannangai R; Chakraborty C; El Allali A; Alsamman AM; Zayed H; C GPD
BMC Infect Dis; 2024 May; 24(1):483. PubMed ID: 38730352
[TBL] [Abstract][Full Text] [Related]
4. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.
Fiscon G; Conte F; Farina L; Paci P
PLoS Comput Biol; 2021 Feb; 17(2):e1008686. PubMed ID: 33544720
[TBL] [Abstract][Full Text] [Related]
5. Repurposing of the antibiotic nitroxoline for the treatment of mpox.
Bojkova D; Zöller N; Tietgen M; Steinhorst K; Bechtel M; Rothenburger T; Kandler JD; Schneider J; Corman VM; Ciesek S; Rabenau HF; Wass MN; Kippenberger S; Göttig S; Michaelis M; Cinatl J
J Med Virol; 2023 Mar; 95(3):e28652. PubMed ID: 36897017
[TBL] [Abstract][Full Text] [Related]
6. Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.
Pizzorno A; Terrier O; Nicolas de Lamballerie C; Julien T; Padey B; Traversier A; Roche M; Hamelin ME; Rhéaume C; Croze S; Escuret V; Poissy J; Lina B; Legras-Lachuer C; Textoris J; Boivin G; Rosa-Calatrava M
Front Immunol; 2019; 10():60. PubMed ID: 30761132
[TBL] [Abstract][Full Text] [Related]
7. Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox.
Peruzzu D; Fecchi K; Venturi G; Gagliardi MC
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240241
[TBL] [Abstract][Full Text] [Related]
8. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing.
Das AB
BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131
[TBL] [Abstract][Full Text] [Related]
9. Drug repurposing for Mpox: Discovery of small molecules as potential inhibitors against DNA-dependent RNA polymerase using molecular modeling approach.
Dutt M; Kumar A; Rout M; Dehury B; Martinez G; Ndishimye P; Kelvin AA; Kelvin DJ
J Cell Biochem; 2023 May; 124(5):701-715. PubMed ID: 36946432
[TBL] [Abstract][Full Text] [Related]
10. Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis.
Cheng F; Murray JL; Zhao J; Sheng J; Zhao Z; Rubin DH
PLoS Comput Biol; 2016 Sep; 12(9):e1005074. PubMed ID: 27632082
[TBL] [Abstract][Full Text] [Related]
11. Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus Agents.
Hishiki T; Morita T; Akazawa D; Ohashi H; Park ES; Kataoka M; Mifune J; Shionoya K; Tsuchimoto K; Ojima S; Azam AH; Nakajima S; Kawahara M; Yoshikawa T; Shimojima M; Kiga K; Maeda K; Suzuki T; Ebihara H; Takahashi Y; Watashi K
Microbiol Spectr; 2023 Aug; 11(4):e0056623. PubMed ID: 37409948
[TBL] [Abstract][Full Text] [Related]
12. Potential therapeutic targets for Mpox: the evidence to date.
Byrareddy SN; Sharma K; Sachdev S; Reddy AS; Acharya A; Klaustermeier KM; Lorson CL; Singh K
Expert Opin Ther Targets; 2023; 27(6):419-431. PubMed ID: 37368464
[TBL] [Abstract][Full Text] [Related]
13. Identification of core therapeutic targets for Monkeypox virus and repurposing potential of drugs against them: An in silico approach.
Sahu A; Gaur M; Mahanandia NC; Subudhi E; Swain RP; Subudhi BB
Comput Biol Med; 2023 Jul; 161():106971. PubMed ID: 37211001
[TBL] [Abstract][Full Text] [Related]
14. Drug repurposing improves disease targeting 11-fold and can be augmented by network module targeting, applied to COVID-19.
Rivero-García I; Castresana-Aguirre M; Guglielmo L; Guala D; Sonnhammer ELL
Sci Rep; 2021 Oct; 11(1):20687. PubMed ID: 34667255
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2-host proteome interactions for antiviral drug discovery.
Liu X; Huuskonen S; Laitinen T; Redchuk T; Bogacheva M; Salokas K; Pöhner I; Öhman T; Tonduru AK; Hassinen A; Gawriyski L; Keskitalo S; Vartiainen MK; Pietiäinen V; Poso A; Varjosalo M
Mol Syst Biol; 2021 Nov; 17(11):e10396. PubMed ID: 34709727
[TBL] [Abstract][Full Text] [Related]
16. Mpox (formerly monkeypox): pathogenesis, prevention, and treatment.
Lu J; Xing H; Wang C; Tang M; Wu C; Ye F; Yin L; Yang Y; Tan W; Shen L
Signal Transduct Target Ther; 2023 Dec; 8(1):458. PubMed ID: 38148355
[TBL] [Abstract][Full Text] [Related]
17. Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments.
Akazawa D; Ohashi H; Hishiki T; Morita T; Iwanami S; Kim KS; Jeong YD; Park ES; Kataoka M; Shionoya K; Mifune J; Tsuchimoto K; Ojima S; Azam AH; Nakajima S; Park H; Yoshikawa T; Shimojima M; Kiga K; Iwami S; Maeda K; Suzuki T; Ebihara H; Takahashi Y; Watashi K
J Infect Dis; 2023 Aug; 228(5):591-603. PubMed ID: 36892247
[TBL] [Abstract][Full Text] [Related]
18. Topological network based drug repurposing for coronavirus 2019.
Habibi M; Taheri G
PLoS One; 2021; 16(7):e0255270. PubMed ID: 34324563
[TBL] [Abstract][Full Text] [Related]
19. Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis.
Adhami M; Sadeghi B; Rezapour A; Haghdoost AA; MotieGhader H
BMC Biotechnol; 2021 Mar; 21(1):22. PubMed ID: 33711981
[TBL] [Abstract][Full Text] [Related]
20. An
Li Z; Yao Y; Cheng X; Li W; Fei T
STAR Protoc; 2021 Sep; 2(3):100653. PubMed ID: 34286288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
